Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Justine L. Lam"'
Autor:
Shaoxian Sun, Sajiv Nair, Simon Planken, Peter A. Wells, Meirong Xu, Greg Stevens, Amy H. Yang, Qing John Li, Darian Bartkowski, Bernadette Pascual, Justine L. Lam, Mary E. Spilker, Allison Rohner
PDF file - 123K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2553d95e87643d370260d09e4a36ff04
https://doi.org/10.1158/1535-7163.22498618
https://doi.org/10.1158/1535-7163.22498618
Autor:
Jan S. Boerma, Luke Fostvedt, Yazdi K. Pithavala, Daria Stypinski, Alfin D. N. Vaz, Theodore R. Johnson, Justine L. Lam
Publikováno v:
Journal of clinical pharmacologyReferences. 60(9)
While an initial clinical absorption, distribution, metabolism, and excretion (ADME) study (Study 1; N = 6) with 100 mg/100 µCi [14 C]lorlatinib, radiolabeled on the carbonyl carbon, confirmed that the primary metabolic pathways for lorlatinib are o
Autor:
Gretchen Jimenez, Rolla Yafawi, Shu-Hui Liu, David L. Shelton, Zhengming Yan, Wenlian Wang, Thomas-Toan Tran, Max Hallin, Tod Smeal, Sherman Michael Chin, Kevin Lindquist, Flavia Pernasetti, Mary E. Spilker, Justine L. Lam, Cathy Zhang, Nanni Huser, Eileen R. Blasi, Colleen Brown, Marco Costa, Brett H. Simmons, Bernadette Pascual, Yin Gu, Valeria Fantin, Jyothirmayee Kudaravalli, Wei-Hsien Ho, Conglin Fan, Ishita Barman, Jing-Tyan Ma
Publikováno v:
Blood Advances. 1:1088-1100
The chemokine receptor CXCR4 is highly expressed and associated with poor prognosis in multiple malignancies. Upon engagement by its ligand, CXCL12, CXCR4 triggers intracellular signaling pathways that control trafficking of cells to tissues where th
Publikováno v:
Xenobiotica. 47:1064-1076
1. The metabolism, excretion and pharmacokinetics of glasdegib (PF-04449913) were investigated following administration of a single oral dose of 100 mg/100 μCi [14C]glasdegib to six healthy male volunteers (NCT02110342). 2. The peak concentrations o
Publikováno v:
Practical Medicinal Chemistry with Macrocycles
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e544b7dde95a547c39ed9b34f43ce80
https://doi.org/10.1002/9781119092599.ch18
https://doi.org/10.1002/9781119092599.ch18
Autor:
Wenyue Hu, Rosa L. Frias, Hovhannes J. Gukasyan, Alice T. Shaw, Valeria Fantin, Ryohei Katayama, Nathan V. Lee, Ruth W. Tang, Timothy Affolter, Eugene Lifshits, Ted William Johnson, Divya Bezwada, David P. Kodack, Lars D. Engstrom, Hieu Lam, Sidra Mahmood, Tod Smeal, Luc Friboulet, Rakesh K. Jain, Hui Wang, Melissa West, Dac M. Dinh, Bhushankumar Patel, Qiuhua Li, Konstantinos Tsaparikos, Helen Y. Zou, Justine L. Lam, Sergei Timofeevski, Shinji Yamazaki, Patrick B. Lappin, Justin F. Gainor, Shibing Deng, Jinwei Wang
Publikováno v:
Cancer Cell. 28:70-81
SummaryWe report the preclinical evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor. Compared with other clinically available ALK inhibitors, PF-06463922 displayed superior potency against all known clinically acquired ALK mut
Autor:
Melissa West, Victoria A. Appleman, Valeria Fantin, Michele McTigue, Sergei Timofeevski, Matthew D. Falk, Alexei Brooun, Scott Rp McDonnell, Tod Smeal, Al Charest, Wenyue Hu, Wei Liu, Ya-Li Deng, Katy A. Wong, Timothy C. Nichols, Justine L. Lam, Ping Jiang, Helen Y. Zou, Qiuhua Li, Lars D. Engstrom, Timothy Affolter, Ted William Johnson, Patrick B. Lappin
Publikováno v:
Proceedings of the National Academy of Sciences. 112:3493-3498
Oncogenic c-ros oncogene1 (ROS1) fusion kinases have been identified in a variety of human cancers and are attractive targets for cancer therapy. The MET/ALK/ROS1 inhibitor crizotinib (Xalkori, PF-02341066) has demonstrated promising clinical activit
Autor:
Sergei Timofeevski, Lars D. Engstrom, Mingying He, Michael R. Collins, Martin Paul Edwards, Phuong Le, Graham L. Smith, John Charles Kath, Helen Y. Zou, Deal Judith G, Ya-Li Deng, Robert Steven Kania, Benjamin J. Burke, Cynthia Louise Palmer, Huichun Zhu, A.E. Stewart, Hieu Lam, Dac M. Dinh, Simon Bailey, Jacqui Elizabeth Hoffman, Neal W. Sach, Robert Louis Hoffman, Qinhua Huang, J. Jean Cui, Alexei Brooun, Wei Liu, Laura Lingardo, Tod Smeal, Ted William Johnson, Michele McTigue, Justine L. Lam, Jinjiang Zhu, Paul F. Richardson
Publikováno v:
Journal of Medicinal Chemistry. 57:4720-4744
Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during treatment eventually develops. Resistant patient samples revealed a variety of point mutations in
Autor:
Tod Smeal, Wei Liu, Huichun Zhu, Simon Bailey, Michael R. Collins, A.E. Stewart, Jacqui Elizabeth Hoffman, Lars D. Engstrom, Graham L. Smith, J. Jean Cui, Ya-Li Deng, Benjamin J. Burke, Laura Lingardo, Phuong Le, Andrew Simon Cook, Konstantinos Tsaparikos, Hieu Lam, Jinjiang Zhu, Ted William Johnson, Neal W. Sach, Dac M. Dinh, Robert Louis Hoffman, Mingying He, Hui Wang, Alexei Brooun, Dack Kevin Neil, Qinhua Huang, Sergei Timofeevski, Deal Judith G, Justine L. Lam, Qiuhua Li, Hong Shen, Melissa West Lu, Michele McTigue, Paul F. Richardson, Kevin D. Bunker, Robert Steven Kania, Martin Paul Edwards, Helen Y. Zou, Cynthia Louise Palmer, Patrick S. Johnson
Publikováno v:
Journal of Medicinal Chemistry. 57:1170-1187
Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 47(12)
1. The metabolism, excretion and pharmacokinetics of glasdegib (PF-04449913) were investigated following administration of a single oral dose of 100 mg/100 μCi [